USD 1.0
(-4.76%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 | - USD | 0.0% |
2023 | - USD | 100.0% |
2022 | -467.57 USD | 66.79% |
2021 | -1408.00 USD | -758.54% |
2020 | -164.00 USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2014 | -648.00 USD | 0.0% |
2013 | -648.00 USD | -30552.79% |
2012 | -2.11 USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q3 | - USD | 0.0% |
2024 Q4 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2024 FY | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 FY | - USD | 100.0% |
2023 Q3 | - USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2022 FY | -467.57 USD | 66.79% |
2022 Q3 | - USD | 100.0% |
2022 Q2 | -83.57 Thousand USD | 78.24% |
2022 Q1 | -384 Thousand USD | 0.0% |
2021 FY | -1408.00 USD | -758.54% |
2021 Q4 | -384 Thousand USD | 0.0% |
2021 Q3 | -384 Thousand USD | 0.0% |
2021 Q1 | -256 Thousand USD | -162.56% |
2021 Q2 | -384 Thousand USD | -50.0% |
2020 Q2 | - USD | 0.0% |
2020 FY | -164.00 USD | 0.0% |
2020 Q4 | -97.5 Thousand USD | -46.62% |
2020 Q3 | -66.5 Thousand USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2015 Q2 | -139.75 Thousand USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q3 | -19.34 Thousand USD | 86.16% |
2014 Q4 | - USD | 0.0% |
2014 FY | -648.00 USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 FY | -648.00 USD | -30552.79% |
2013 Q1 | - USD | 100.0% |
2012 Q4 | -0.18 USD | 0.0% |
2012 FY | -2.11 USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
GSRX Industries Inc. | - USD | NaN% |
High Sierra Technologies, Inc. | -56.39 Thousand USD | 100.0% |
Instadose Pharma Corp. | - USD | NaN% |